Post by Swiss Business Hub USA

From ETH Zürich spin-off to IPO: Switzerland’s ecosystem helps biotech build investor confidence. 📈🧬    The Swiss Biotech Report 2026 highlights a notable milestone: BioVersys AG became the first SIX biotech IPO since 2018.    In February 2025, BioVersys listed on SIX Swiss Exchange with a CHF 80 million fixed-price offering  (the largest biotech IPO in Europe in five years) to advance a late-stage pipeline targeting drug-resistant infections.    In the interview, CEO and co-founder Marc Gitzinger shares what investors focused on:  📌 A clear equity story (unmet need, program maturity, pipeline depth, differentiation and IP)  📊 Clinical data that de-risks the path ahead  👥 A leadership team ready for the complexity of being public    📰 Read the full article by Fabian Gerber (SIX) in the Swiss Biotech Report 2026: https://lnkd.in/eqR29A8p    📄 Download the full report: https://lnkd.in/gfkz7FH #WhySwitzerland #SwissInnovation #LifeSciences #BioTech #SwissBiotechReport2026 Swiss Biotech Association EY scienceindustries Swiss National Science Foundation SNSF Swiss Federal Institute of Intellectual Property IGE IPI Swiss Academy of Engineering Sciences SATW Swissmedic Switzerland Global Enterprise SIX swisstech Switzerland Innovation Swissnex Presence Switzerland Basel Area Business & Innovation Basel Area Life Sciences Supercluster Greater Geneva Bern area (GGBa) Greater Zurich Area Standortförderung St.Gallen Kanton Appenzell Ausserrhoden Kanton Appenzell I.Rh. Economic Development Office Thurgau Lucerne Business Economic Promotion Valais Standortförderung Kanton Aargau Brigitte Fäh Standort Promotion in Obwalden Biopôle Lausanne BioAlps - Swiss Health Valley BioArk